Undesirable gynaecological and operative interventions during treatment of breast cancer with Anastrozole and Tamoxifen;Unerwünschte gynäkologische und operative interventionen bei der behandlung des postmenopausalen mammakarzinoms mit Anastrozol und Tamoxifen

Geburtshilfe und Frauenheilkunde

Volumn 70, Issue 1, 2010, Pages 57-61

  Distler, W ^a   Canzler, U ^a   Duffy, S R ^b   Howell, A ^c   Cuzick, J ^d   Baum, M ^e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anastrozole; Early breast cancer; Gynaecological adverse events; Tamoxifen

Indexed keywords

ANASTROZOLE; HORMONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLPOSCOPY; CONTROLLED STUDY; CURETTAGE; DYSPAREUNIA; ECHOGRAPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; GENITAL TRACT INFECTION; GYNECOLOGIC CARE; GYNECOLOGIC SURGERY; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; INCIDENCE; LAPAROSCOPY; LEUKORRHEA; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; OVARIECTOMY; OVARY CANCER; OVARY DISEASE; POLYPECTOMY; POSTMENOPAUSE; RETROSPECTIVE STUDY; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERUS; UTERUS CANCER; VAGINA BLEEDING; VAGINA PAIN; VAGINA RECONSTRUCTION;

EID: 75649122890     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1240720     Document Type: Article

References (17)

1. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 365 60-62
2. Bergman L, Beelen M L., Gallee M P. et al, Comprehensive Cancer Centres' ALERT Group, Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000 356 881-887
3. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003 361 296-300
4. Distler W, für die ATAC-Studiengruppe. Gynäkologische Langzeitsicherheit in der ATAC-Studie: Weniger Nebenwirkungen, operative Interventionen und Endometriumanomalien unter Anastrozol als unter Tamoxifen bei Frauen mit Mammakarzinom in der Postmenopause. Senologie 2007 4 108 (Abstr. 13)
5. Duffy S R., Jackson T L., Landsdown M et al. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006 21 545-553
6. Duffy S R., Distler W, Howell A et al. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol 2009 200 80-82
7. COSTART. Coding symbols for thesaurus of adverse reactions terms. 5th ed. Rockville Food and Drug Administration 1995
8. Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996 74 1286-1291
9. Hillner B E. Benefit and projected cost-effectiveness of anastrozole versus Tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004 101 1311-1322
10. Karnon J. Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer. Expert Rev Pharmaoeconomics Outcomes Res 2007 7 143-153 (Pubitemid 46690968)
11. Locker G Y., Mansel R, Cella D et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. 5-year completed treatment analysis of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 2008 106 229-238
12. Shapiro C L. Aromatase inhibitors and bone loss: risk in perspective. J Clin Oncol 2005 23 4847-4849
13. The Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008 9 45-53
14. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002 359 2131-2139
15. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen, alone or in Combination) trial efficacy and safety update analyses. Cancer 2003 98 1802-1810
16. The ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006 7 633-643
17. Van Leeuwen F E., Benraadt J, Coebergh J W. et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994 343 448-452